TORONTO--(BUSINESS WIRE)--Fulcrum IT Partners ("Fulcrum") announces the successful acquisition of F3 Technology Partners (“F3”), marking the company's second U.S. acquisition and fourth global ...

Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn ...

As of February 10, 2023, the average one-year price target for Fulcrum Therapeutics is $23.01. The forecasts range from a low of $8.08 to a high of $36.75. The average price target represents an ...

Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027. The ...

Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―― 20 mg ...

After four months, Fulcrum Therapeutics finally has a permanent CEO: industry veteran Alex Sapir. The clinical-stage biopharmaceutical company named Sapir as its leader Monday, four months after CEO ...

TORONTO, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Fulcrum Capital Partners (Fulcrum) is pleased to announce the sale of its equity ownership interest in Skyservice Investments Inc. (Skyservice). The sale ...